Avita MedicalRCEL
About: Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.
Employees: 207
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
50% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 16
33% more capital invested
Capital invested by funds: $49.4M [Q2] → $65.7M (+$16.3M) [Q3]
0% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 12
0.57% less ownership
Funds ownership: 24.15% [Q2] → 23.58% (-0.57%) [Q3]
5% less call options, than puts
Call options by funds: $423K | Put options by funds: $447K
1% less funds holding
Funds holding: 68 [Q2] → 67 (-1) [Q3]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Lake Street Brooks O'Neil 46% 1-year accuracy 6 / 13 met price target | 62%upside $14 | Buy Maintained | 8 Jan 2025 |
D. Boral Capital Jason Kolbert 39% 1-year accuracy 74 / 190 met price target | 189%upside $25 | Buy Maintained | 8 Jan 2025 |
Cantor Fitzgerald Ross Osborn 48% 1-year accuracy 23 / 48 met price target | 143%upside $21 | Overweight Reiterated | 24 Dec 2024 |
Piper Sandler Matt O'Brien 57% 1-year accuracy 29 / 51 met price target | 39%upside $12 | Neutral Reiterated | 8 Nov 2024 |
Financial journalist opinion
Based on 8 articles about RCEL published over the past 30 days
